The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

Menon, Usha, McGuire, Alistair J., Raikou, Maria, Ryan, Andy, Davies, Susan K., Burnell, Matthew, Gentry-Maharaj, Aleksandra, Kalsi, Jatinderpal K., Singh, Naveena, Amso, Nazar N., Cruickshank, Derek, Dobbs, Stephen, Godfrey, Keith, Herod, Jonathan, Leeson, Simon, Mould, Tim, Murdoch, John, Oram, David, Scott, Ian, Seif, Mourad W., Williamson, Karin, Woolas, Robert, Fallowfield, Lesley, Campbell, Stuart, Skates, Steven J., Parmar, Mahesh and Jacobs, Ian J. (2017) The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). British Journal of Cancer, 117 (5). 619 - 627. ISSN 0007-0920

Preview

Text - Published Version Available under License Creative Commons Attribution. Download (570kB) | Preview

Abstract

Background: To assess the within-trial cost-effectiveness of an NHS ovarian cancer screening (OCS) programme using data from UKCTOCS and extrapolate results based on average life expectancy. Methods: Within-trial economic evaluation of no screening (C) vs either (1) an annual OCS programme using transvaginal ultrasound (USS) or (2) an annual ovarian cancer multimodal screening programme with serum CA125 interpreted using a risk algorithm (ROCA) and transvaginal ultrasound as a second-line test (MMS), plus comparison of lifetime extrapolation of the no screening arm and the MMS programme using both a predictive and a Markov model. Results: Using a CA125–ROCA cost of £20, the within-trial results show USS to be strictly dominated by MMS, with the MMS vs C comparison returning an incremental cost-effectiveness ratio (ICER) of £91 452 per life year gained (LYG). If the CA125–ROCA unit cost is reduced to £15, the ICER becomes £77 818 per LYG. Predictive extrapolation over the expected lifetime of the UKCTOCS women returns an ICER of £30 033 per LYG, while Markov modelling produces an ICER of £46 922 per QALY. Conclusion: Analysis suggests that, after accounting for the lead time required to establish full mortality benefits, a national OCS programme based on the MMS strategy quickly approaches the current NICE thresholds for cost-effectiveness when extrapolated out to lifetime as compared with the within-trial ICER estimates. Whether MMS could be recommended on economic grounds would depend on the confirmation and size of the mortality benefit at the end of an ongoing follow-up of the UKCTOCS cohort

Item Type:	Article
Official URL:	http://www.nature.com/bjc/index.html
Additional Information:	© 2017 The Authors © CC BY 4.0
Divisions:	Social Policy LSE Health
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Date Deposited:	18 Sep 2017 08:19
Last Modified:	06 Apr 2024 03:54
URI:	http://eprints.lse.ac.uk/id/eprint/84234

Actions (login required)

View Item